New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
September 14, 2017 – The FDA announced the approval of Bayer’s Aliqopa (copanlisib) for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies.
Download PDF
Return to publications
